Effects of donor plasma and recipient characteristics on convalescent plasma treatment outcome of COVID-19

供体血浆和受体特征对 COVID-19 恢复期血浆治疗结果的影响

• 批准号: 10225219
• 负责人: Maria Laura Gennaro
• 金额: $ 75.39万
• 依托单位: RBHS-NEW JERSEY MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-01 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10225219
• 关键词: 2019-nCoV; Affect; Antibodies; Antibody Response; Antibody titer measurement; Antibody-Dependent Enhancement; Antigen Targeting; Biological Assay; Biological Markers; Blood; Blood Cell Count; Blood Cells; Blood Donations; Blood Transfusion; COVID-19; COVID-19 pandemic; Cells; Cessation of life; Characteristics; Clinical; Clinical Practice Guideline; Clinical Trials; Coagulation Process; Communicable Diseases; Complete Blood Count; Consent; Convalescent Hospitals; Critical Care; Development; Disease; Emergency Situation; Emergency treatment; FDA approved; Future; Hematologist; Hospitals; Immune; Immune response; Immunologic Markers; Immunologist; Immunophenotyping; Inflammatory Response; Infrastructure; Infusion procedures; Knowledge; Life; Link; Lung; New Brunswick; Outcome; Oxygen; Patients; Pharmaceutical Preparations; Pharmacology; Phenotype; Physicians; Plasma; Plasmapheresis; Property; Proteins; Protocols documentation; Reagent; Research; Resources; Respiratory System; Sampling; Severities; Side; Symptoms; Teaching Hospitals; Techniques; Testing; Therapeutic; Transfusion; Treatment Efficacy; Treatment outcome; University Hospitals; Viral Load result; Wood material; antibody-dependent cell cytotoxicity; cytokine; design; effectiveness evaluation; inflammatory marker; knowledge of results; medical schools; multidisciplinary; neutralizing antibody; novel; prognostic; programs; success; transfusion medicine

In the absence of FDA-approved pharmacological therapies, convalescent plasma infusion has rapidly emerged as a notable emergency therapy for severe cases of COVID-19. However, due to the emergency conditions under which this treatment has been practiced, little effort has been placed in characterizing the properties of the donor plasma and the clinical status of the COVID- 19 patients that can most benefit from the infusion. We have assembled a multidisciplinary team that leverages linked blood donation and blood transfusion programs at Robert Wood Johnson University Hospital and state-of-the-art resources for the study of antibody responses and plasma markers of COVID-19 severity. This team proposes to conduct a study that relates donor plasma properties (antibody titers and functions, and antigen targets) and recipient's clinical status (including peripheral blood cell immunophenotypes and various plasma markers of COVID-19 severity) to the success of convalescent plasma infusion. The new knowledge resulting from our plan will guide the development of rational clinical practice guidelines and the design of convalescent plasma clinical trials.

在没有FDA批准的药理疗法的情况下，康复血浆输注已迅速成为严重的Covid-19病例的显着紧急疗法。但是，由于已实践这种治疗的紧急情况，几乎没有努力表征供体等离子体的特性以及Covid-19例患者的临床状况，这可以从输注中受益最大。我们已经组建了一个多学科团队，该团队利用罗伯特·伍德·约翰逊大学医院的血液捐赠和输血计划和最先进的资源联系在一起，以研究Covid-19的严重程度的抗体反应和等离子体标记。该团队建议进行一项研究，该研究将供体等离子体特性（抗体滴度和功能，抗原靶标）和接受者的临床状况（包括外周血血细胞免疫表型和COVID-19的各种等离子体标记）与溶解血浆输注的成功。我们计划产生的新知识将指导制定理性临床实践指南和康复等离子体临床试验的设计。